Profile data is unavailable for this security.
About the company
Ginwa Enterprise Group Inc is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company operates its businesses through three segments. The Pharmaceutical Industry segment is mainly engaged in the production of pharmaceuticals. The Company's products are divided into four series, including orthopedics, immunology, children's and general medicines, mainly covering chemicals, Chinese patent medicines, active pharmaceutical ingredient and health care products. The Hotel Industry segment is mainly engaged in the operation of hotels. The Pharmaceutical Commercial segment is mainly engaged in the sales of pharmaceuticals. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)581.53m
- Net income in CNY-15.51m
- Incorporated1996
- Employees553.00
- LocationGinwa Enterprise Group IncNo. 202 Science 4th Road, Hi-tech ZoneXI'AN 710075ChinaCHN
- Phone+86 2 988336635
- Fax+86 2 981778626
- Websitehttp://www.ginwa.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novoprotein Scientific Inc | 134.56m | -21.29m | 2.41bn | 579.00 | -- | 1.12 | -- | 17.89 | -0.3031 | -0.3031 | 1.92 | 30.57 | 0.0592 | 0.5833 | 1.96 | 232,406.80 | -0.937 | -- | -0.959 | -- | 61.17 | -- | -15.82 | -- | 34.60 | -- | 0.0323 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Ginwa Enterprise Group Inc | 581.53m | -15.51m | 2.48bn | 553.00 | -- | 1.63 | -- | 4.27 | -0.0382 | -0.0382 | 1.58 | 4.07 | 0.2968 | 4.81 | 5.28 | 1,051,591.00 | -0.7916 | 0.3641 | -0.9515 | 0.4141 | 76.18 | 73.64 | -2.67 | 1.15 | 2.19 | 0.196 | 0.0431 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 732.68m | 166.02m | 2.62bn | 738.00 | 15.77 | 2.10 | -- | 3.57 | 0.5072 | 0.5072 | 2.24 | 3.80 | 0.4013 | 2.01 | 17.68 | 992,793.70 | 9.07 | 12.01 | 11.17 | 14.75 | 66.13 | 69.79 | 22.60 | 22.84 | 1.01 | -- | 0.1998 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Holder | Shares | % Held |
|---|---|---|
| Baoying Fund Management Co., Ltd.as of 30 Jun 2024 | 165.00k | 0.05% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 56.00k | 0.02% |
| Sealand Securities Co., Ltd. (Investment Management)as of 30 Jun 2024 | 33.20k | 0.01% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 25.10k | 0.01% |
| Peng Yang Amc Fund Management Co. Ltd.as of 30 Jun 2024 | 100.00 | 0.00% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 0.00 | 0.00% |
| Tebon Fund Management Co. Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
